Reviva Pharmaceuticals Holdings, Inc.

Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company dedicated to developing innovative therapeutics addressing unmet medical needs, particularly in neuropsychiatry, metabolic diseases, and respiratory disorders. Established in 2006, Reviva Pharmaceuticals Holdings, Inc. is headquartered in Santa Clara, US, focusing on the development of therapeutics for neuropsychiatric conditions.

The company, founded by Laxminarayan Bhat, has successfully completed multiple funding rounds, with its most recent funding being a Private Placement of USD 8. 5 mn in September 2022, bringing the total amount raised to USD 8. 5 mn. Reviva operates independently and has conducted 7 Deals since its inception, with the latest deal recorded on May 26, 2021.

Reviva Pharmaceuticals Holdings, Inc. specializes in developing therapeutics for significant unmet medical needs, particularly targeting conditions like schizophrenia, bipolar disorder, and ADHD. Their lead product, brilaroxazine (RP5063), is in clinical development for various neuropsychiatric conditions and leverages advanced technology to enhance treatment safety and efficacy. Reviva's products are aimed primarily at healthcare providers and mental health professionals in North America and Europe, addressing the needs of patients affected by complex medical conditions.

Reviva Pharmaceuticals operates on a revenue model that relies on partnerships with healthcare entities and research institutions to advance its product pipeline. Revenue is generated through business-to-business transactions with pharmaceutical distributors, milestone payments from partnerships, and future product sales upon regulatory approval. They focus on securing collaborations to support the commercialization of brilaroxazine, which is expected to diversify their revenue streams as products enter the market, while specific pricing structures remain undisclosed. Reviva Pharmaceuticals Holdings, Inc.

plans to utilize the proceeds from its recent funding initiatives to support the continued development of brilaroxazine and expansion into new markets. The company aims to launch this product in the coming years while targeting additional regions for market entry. Following their strategic merger with Tenzing Acquisition Corp. in December 2020, the company is positioned to explore growth opportunities and enhance its product offerings, with aspirations for further collaborations that align with their business model.